Vaccines for whatever ails you. Toxic load will kill you.
One Click Note: With drug patents expiring and very few new drugs in the pipeline, the pharmaceutical industry has now gripped on to vaccines as the greatest profit block buster of all time. No matter that the spreading Polio epidemics in Nigeria have been caused by the Polio vaccine itself, no matter the multiple million vaccines body count of the previously healthy now disabled and dead, crushed under the pharmaceutical industry juggernaut. The Swine Flu Panic has been one of the most sophisticated and lucrative marketing scams of all time. Far from being reined in by politicians and governments, the pharmaceutical industry is now enjoying a golden era by playing Russian Roulette with your lives and those of your children.
19 Nov. 2009
Vaccines on horizon for AIDS, Alzheimer’s, herpes
By LINDA A. JOHNSON (AP)
MARIETTA, Pa. — Malaria. Tuberculosis. Alzheimer’s disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler’s diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.
Many could be on the market in five years or less.
Contrast that with five years ago, when so many companies had abandoned the vaccine business that half the U.S. supply of flu shots was lost because of factory contamination at one of the two manufacturers left.
Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they’re starting to give ailing pharmaceutical makers a shot in the arm.
The lure of big profits, advances in technology and growing government support has been drawing in new companies, from nascent biotechs to Johnson & Johnson. That means recent remarkable strides in overcoming dreaded diseases and annoying afflictions likely will continue.
“Even if a small portion of everything that’s going on now is successful in the next 10 years, you put that together with the last 10 years (and) it’s going to be characterized as a golden era,” says Emilio Emini, Pfizer Inc.’s head of vaccine research.
Vaccines now are viewed as a crucial path to growth, as drugmakers look for ways to bolster slowing prescription medicine sales amid intensifying generic competition and government pressure to cut down prices under the federal health overhaul.